Martin E Schwab

This inventor holds 12 USPTO granted patents and 3 published patent applications, plus 4 CIPO patents and 2 EPO patents. Top assignees: Unversität Zürich, Erziehungsdirektion of the Canton Zurich, Novartis Ag. Active years: 1993-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martin E Schwab. Retrieved from https://idiyas.com/inventor/martin-e-schwab

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 3)

% Patents Active = 58.3

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 3.2

ph-index = 4

Forward Citations = 112(Granted Patents)

Location History:

Zurich, CH (1993 - 2014)
Zürich, CH (2010 - 2014)

Company Filing History:

Erziehungsdirektion of the Canton Zurich

where one patent can have more than one assignee

Years Active: 1993-2014

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8828390 - Uses of NOGO-A inhibitors and related methods (2014-09-09),

2. 8758754 - Nogo-A binding molecules and pharmaceutical use thereof (2014-06-24),

3. 8535666 - Antibody (11C7) anti Nogo-A and its pharmaceutical use (2013-09-17),

4. 8163285 - Nogo-A binding molecules and pharmaceutical use thereof (2012-04-24),

5. 7785593 - Antibody (11C7) anti nogo a and its pharmaceutical use (2010-08-31),

6. 7781188 - Nucleotide and protein sequences of Nogo genes and methods based thereon (2010-08-24),

7. 7425334 - Methods of making antibodies that bind Nogo (2008-09-16),

8. 6960559 - Neurite growth regulatory factors (2005-11-01),

9. 6103232 - Neurite growth regulatory factors (2000-08-15),

10. 6025333 - Treatment of CNS tumors with metalloprotease inhibitors (2000-02-15),

11. 5684133 - Neurite growth regulatory factors, antibodies thereto, and (1997-11-04),

12. 5250414 - Diagnostic methods using neurite growth regulatory factors (1993-10-05),

Title: The Innovative Contributions of Martin E Schwab

Introduction

Martin E Schwab is an esteemed inventor based in Zurich, Switzerland, known for his significant contributions to the field of neuroscience and diabetes treatment. With an impressive portfolio of 12 patents, Schwab's work has evolved the understanding of Nogo-A and its implications in blood glucose and insulin regulation.

Latest Patents

Among Schwab's notable patents is the invention titled "Uses of NOGO-A inhibitors and related methods." This invention focuses on Nogo-A antagonists that are instrumental in controlling blood glucose and insulin levels in individuals. It particularly addresses the prevention, repression, or treatment of insulin secretion deficiency, which is crucial for managing diabetes mellitus. Another groundbreaking patent from Schwab is "Nogo-A binding molecules and pharmaceutical use thereof." This invention describes a binding molecule capable of binding to the human NogoA polypeptide and provides a variety of applications for treating diseases of the peripheral and central nervous systems.

Career Highlights

Throughout his career, Martin E Schwab has garnered valuable experience while working with esteemed organizations. He has served in the Erziehungsdirektion of the Canton Zurich, where he contributed to educational reform and development. Additionally, Schwab has worked with Novartis AG, a leading global healthcare company, where his work has driven significant advancements in pharmaceutical sciences.

Collaborations

Collaboration has been a vital aspect of Schwab's innovative journey. He has closely worked with prominent colleagues such as Pierenrico W Caroni and Paolo A Paganetti. Their collaborations have fostered new research avenues and improved multidisciplinary approaches to scientific challenges.

Conclusion

Martin E Schwab stands out as a key figure in the realm of medical innovations. His inventions, particularly in the areas of diabetes treatment and neurobiology, have immense potential to change lives. As he continues to build upon his research, the impact of his work will likely resonate within the scientific community and beyond.

Profile summary based on public USPTO records.